PBAC recommends listing of meningococcal B vaccine on NIP for at risk groups

7 January 2020

 

The recommendations from the November 2019 Pharmaceutical Benefits Advisory Committee (PBAC) meeting are now available which includes the PBAC recommendation for the listing of multicomponent meningococcal group B vaccine (4CMenB, Bexsero®)

The PBAC recommended the listing of multicomponent meningococcal group B vaccine (4CMenB, Bexsero®), on the NIP, for the prevention of invasive meningococcal disease (IMD) in Aboriginal and Torres Strait Islander children and the implementation of a catch-up program for Aboriginal and Torres Strait Islander children up to 2 years of age.

The PBAC also considered 4CMenB was likely to be cost-effective in children and adults with medical conditions associated with increased risk of IMD (specifically, people with asplenia and hyposplenia, complement deficiency and those undergoing treatment with eculizumab) and recommended listing on the NIP for routine vaccination of this population.

The PBAC did not recommend listing for a broader population of infants or for adolescents due to the remaining uncertainties regarding the magnitude of clinical effectiveness of 4CMenB, and the lack of any herd protective effects, which inform the cost effectiveness.

The PBAC recommendations are available here (detailed under positive recommendations).